Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 2

Are you treating patients with advanced chronic myeloid leukemia (accelerated phase or blast crisis) any differently during the COVID-19 pandemic?

Recorded April 24, 2020.

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 3

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 4

At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?

Recorded April 24, 2020.

COVID-19

Derek Raghavan, MD, PhD, on COVID-19 and Cancer Care: The View From North Carolina

Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, and a member of The ASCO Post Editorial Board, discusses the ways in which COVID-19 has affected oncology care in his community, and some practical tips that may help fellow providers. Filmed April 9, 2020.

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 4

For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19?

Recorded April 24, 2020.

Advertisement

Advertisement




Advertisement